
It wasn’t long ago when Wall Street loved weight-loss drug makers almost as much as companies involved with artificial intelligence (AI).
But that love was short-lived, and has turned into Wall Street’s version of hate - selling a stock.

It wasn’t long ago when Wall Street loved weight-loss drug makers almost as much as companies involved with artificial intelligence (AI).
But that love was short-lived, and has turned into Wall Street’s version of hate - selling a stock.